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 1 
Abstract (246 words) 2 
Objective: We investigated adherence barriers to inhaled medicines among older 3 
compared to younger adults with asthma in Japan. 4 
Methods: Adherence barriers to inhaled medicines were evaluated in 251 Japanese older 5 
(n = 138) and younger (n = 113) adults with asthma using the self-reporting “Adherence Starts 6 
with Knowledge 20” (ASK-20) questionnaire. 7 
Results: There were fewer older adults with poor adherence to inhaled medicines than 8 
younger adults. The ASK-20 questionnaire revealed (odds ratio [95% confidence interval]) 9 
item Q11 (“My doctor/nurse and I work together to make decisions”; 2.94 [1.31, 6.61]; p < 10 
0.05) as an independent adherence barrier to inhaled medicines among older adults, 11 
whereas younger adults reported item Q3 (“My use of alcohol gets in the way of taking my 12 
medicines”; 3.91 [1.02 to 15.1]; p < 0.05) and item Q16 (“Taken a medicine more or less 13 
often than prescribed? “; 2.31 [1.32 to 4.06]; p < 0.05) as barriers. Older adults with poor 14 
adherence identified item Q1 (“I just forget to take my inhaled medicines some of the time”; 15 
4.43 [1.77, 11.1]; p < 0.05) as a barrier, although the total ASK-20 scores and total barrier 16 
counts were significantly higher in older (both, p < 0.05) and younger (both, p < 0.05) adults 17 
with poor adherence than in those with good adherence. 18 
5 
 
Conclusion: Older Japanese patients had better adherence to inhaled medicines than 1 
younger patients. Barriers were different between older and younger adults. These results 2 
will help personalize education for inhaled medicines in Japanese asthmatics. 3 
 4 
 5 
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Introduction 1 
The World Health Organization (WHO) predicts that the proportion of people aged 65 years 2 
and older will grow from an estimated 524 million in 2010 to 1.5 billion by 2050 [1]. Japan is 3 
now considered a “super-aged” society, with older adults (age ≥65 years) already making up 4 
more than 27% of the population in 2016 [2]. Recently, mortality due to asthma has been 5 
decreasing, but in Japan, over 90% of fatal asthmatics are older adults [3]. Among older 6 
adults with uncontrolled asthma, physicians tend to under-prescribe inhaled corticosteroids 7 
(ICS) because of concern over the side effects of these medicines [4], even though regular 8 
use of ICS plays a central role in controlling the chronic airway inflammation of asthma, and 9 
can also improve quality of life and attenuate the exacerbations and mortality in patients with 10 
asthma [5]. Low rates of adherence to the regular use of controllers for asthma might 11 
contribute to this disease being poorly controlled among older patients [6], [7]. Previous 12 
reports [8], [9], [10], [11], [12] demonstrated that adherence rates to ICS use in older adults 13 
with asthma were lower than those in the total population with asthma. However, a 14 
meta-analysis did not report that age was significantly associated with adherence rates to 15 
inhaled medicines [13]. Furthermore, a previous Japanese report demonstrated that 16 
increased age was associated with better adherence scores to inhaled medicines [14]. 17 
However, efforts to address this issue, through education and interventions to improve 18 
7 
 
adherence to inhaled medicine regimes, may be more successful among older adults with 1 
asthma than among younger patients with asthma [13], [15], [16]. 2 
Adherence rates and barriers to inhaled medicines among older adults with asthma 3 
in Japan are still unclear. However, evaluating individual barriers may contribute to 4 
improvements in adherence rates for inhaled medicines, including ICS, by helping address 5 
unmet education and intervention needs. The Adherence Starts with Knowledge 20 6 
(ASK-20) questionnaire was developed by Hahn et al for identifying barriers [17], [18] and 7 
the Japanese version of the ASK-20 questionnaire has already been validated in Japanese 8 
patients with asthma [19]. Previous studies have demonstrated good correlation between 9 
adherence and barriers in patients with asthma by using the ASK-20 questionnaire [17], [18], 10 
[19], [20]. However, the generalizability of the questionnaire remains limited, because the 11 
questionnaire has only been evaluated in English and Japanese. Building on this work, the 12 
Kyushu Asthma Seminar Investigator Group conducted a multicenter, cross-sectional, 13 
non-interventional trial to investigate adherence and barriers to inhaled medicines among 14 
older adults compared to younger adults with asthma using the ASK-20 questionnaire in 15 
Japan.  16 
 17 
18 
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 1 
Methods 2 
Ethical approval 3 
The study was conducted in accordance with the Good Clinical Practice guidelines and was 4 
approved by the ethics board of each institute. The trial was registered in the University 5 
Hospital Medical Information Network (UMIN) Center (UMIN No. R000015329) on February 6 
13, 2014. Physicians obtained written informed consent from every patient who met the 7 
inclusion criteria. 8 
 9 
Selection of patients, and inhaled and oral medicines 10 
Japanese adult (age >20 years) patients with asthma who met the inclusion criteria—regular 11 
medication with at least one inhaled medicine, including regular use of ICS, regular clinic 12 
attendance with medical records since giving consent for participation within 6 months or 13 
more before the start of the study—were enrolled at each institute. To investigate adherence 14 
in each patient, one inhaled medicine was selected as the most important among all 15 
regularly prescribed medicines by the patient’s physician, without consultation with the 16 
patient (Supplementary Table 1). 17 
 18 
9 
 
Study design 1 
After providing written consent, patients were required to complete the Japanese version of 2 
the self-reporting ASK-20 questionnaire for adherence to the selected inhaled medicines 3 
[19]. Patient characteristics—including age, sex, body mass index (BMI), smoking habits, 4 
presence of comorbid diseases, disease control levels, adherence levels to the selected 5 
inhaled medicines, and information on all regular inhaled and oral medications—were 6 
recorded. Diagnosis of asthma and asthma controlled levels were defined in accordance 7 
with the Global Initiative for Asthma (GINA) reports [5]. Comorbid diseases were defined on 8 
the basis of interview findings and information regarding all regular medicines prescribed to 9 
the study population (Supplementary Table 2). From medical records, physicians selected 10 
the best pre-bronchodilation values of forced vital capacity (FVC) and forced expiratory 11 
volume in 1 s (FEV1) during stable disease status. Adherence to the selected inhaled 12 
medicines within 6 months before enrolment was assessed on the basis of questionnaire 13 
findings and prescription refill methods, and poor (< 80% of adherence) and good (> 80% of 14 
adherence) adherence were defined by either method [21], [22], [23], [24] [25]. However, 15 
each patient was required to self-report one of the following four categories of adherence 16 
levels, namely, 100%, <100% and >80%, <80% and >50%, and <50% of adherence within 6 17 
10 
 
months, in accordance with previous studies [21] [22] [23] [24] [25] that used questionnaire 1 
methods. All data were obtained within the 6 months before enrolment. 2 
 3 
Statistical analysis 4 
Patient characteristics were expressed as number (percentage) of patients or mean ± 5 
standard deviation (SD). Total ASK-20 scores and total barrier counts (TBCs) for adherence 6 
to the selected inhaled medicines were calculated in accordance with the methods 7 
described in previous studies [17], [18], [19], [20]. To investigate adherence rates and 8 
barriers among older patients, the adherence parameters were compared between older 9 
(age > 65 years) and younger (age >20 years and <65 years) adults after evaluating each 10 
age group. The cutoff of 65 years in Japan as developed country was based on a WHO 11 
report [1]. In addition, the patients were divided into four groups ― those with poor and good 12 
adherence to the selected inhaled medicines in older and younger adults, respectively. The 13 
proportions of patients with poor adherence, and the median values (lower and higher 14 
percentiles) of total ASK-20 scores and TBCs of inhaled medicines were compared between 15 
older and younger adults. Comparative analysis between two groups was performed by 16 
using the two-tailed unpaired t-test or non-parametric Wilcoxon test, and the chi-squared 17 
test or Fisher’s exact test with an expected frequency of <5.0 in cells >20%. Total ASK-20 18 
11 
 
scores and TBCs among age groups were compared by using the non-parametric Wilcoxon 1 
test with Steel-Dwass correction. To identify the barriers to inhaled medicines, the odds ratio 2 
(95% confidence interval [CI] and p value) was analyzed by the chi-square or Fisher’s exact 3 
test in univariate and multivariate logistic regression analyses. Differences at p < 0.05 were 4 
considered statistically significant. Statistical analyses were performed using the software 5 
package JMP version 9.0 (SAS Institute Japan Inc., Tokyo, Japan). 6 
7 
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 1 
Results 2 
Two hundred and eighty-three patients provided written consent, and 251 patients (older [n 3 
= 138] and younger [n = 113] adults; mean age 63.2 years [range 26 to 90 years]) were 4 
finally analyzed in the study (Figure 1). Among age groups, an age group between 75 years 5 
and 84 years was the smallest population of patients with poor adherence to inhaled 6 
medicines (p = 0.328) and the proportions were like an inverted J-character curve from 25 7 
years to 85 or more years (Figure 2A). The age group of 85 or more years had a greater, but 8 
not significantly so, population with poor adherence to inhaled medicines than the age group 9 
between 75 and 84 years (p = 0.594) (Figure 2A). The population of patients with poor 10 
adherence to inhaled medicines was 24.3% of total study population. In terms of poor 11 
adherence, the population with older adults was smaller, but not significantly so, than the 12 
younger adults (p = 0.107) (Figure 2B).  13 
Table 1 presents a comparison of characteristics between older and younger adults. 14 
Older adults had significantly less proportions of current smokers and regular/part-time 15 
workers, and lower pulmonary functions, and had a higher proportion of patients with regular 16 
use of mucolytic agents than younger adults. In regular treatment, the number of oral 17 
13 
 
medicines in older adults was significantly higher than that in younger ones, although there 1 
was no difference in the number of inhaled medicines between the two groups. 2 
As shown in Figure 3, the median of total ASK-20 scores, but not of TBCs (p>0.05), 3 
for older adults was significantly less than that for younger adults (p = 0.037). Figure 4 4 
presents the comparison between the proportion of older and younger adults with barriers to 5 
inhaled medicines identified for each ASK-20 item. A significantly higher proportion of older 6 
adults reported the ASK-20 item Q10 (“I understand my doctor’s/nurse’s instructions about 7 
the medicines I take”) and item Q11 (“My doctor/nurse and I work together to make 8 
decisions”), whereas a higher proportion of younger adults reported item Q3 (“My use of 9 
alcohol gets in the way of taking my medicines”) and item Q16 (“Taken a medicine more or 10 
less often than prescribed? “) as barriers to inhaled medicines. Multivariate analyses found 11 
that the item Q11 (odds ratio, 2.94 [95% CI, 1.31 to 6.61]; p = 0.009) was an independent 12 
barrier among older adults, whereas the items Q3 (3.91 [1.02 to 15.1]; p = 0.048] and Q16 13 
(2.31 [1.32 to 4.06]; p = 0.004) were independent barriers among younger adults (full 14 
analyses in Supplementary Table 3). 15 
Figure 5 presents the results of the comparison of total ASK-20 scores and TBCs 16 
between patients with poor and good adherence to selected inhaled medicines in older and 17 
younger adults. Both older and younger adult groups with poor adherence had significantly 18 
14 
 
higher total ASK-20 scores and TBCs than those with good adherence. Multivariate 1 
analyses found that older adults patients with poor adherence had item Q1 (“I just forget to 2 
take my medicines some of the time”; odds ratio, 4.43 [95% CI, 1.77 to 11.1]; p = 0.001) as 3 
an independent barrier, whereas younger adults with poor adherence had items Q1 (6.88 4 
[1.94 to 24.4]; p = 0.003], Q4 (“I worry about how medicine will affect my sexual health”; 7.43 5 
[1.15 to 46.6]; p = 0.035), and Q20 (“Not had medicine with you when it was time to take it?”; 6 
4.14 [1.08 to 15.9]; p = 0.038) as independent barriers to inhaled medicines. 7 
 8 
9 
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 1 
Discussion 2 
To our knowledge, this is the first report comparing adherence ratios and adherence barriers 3 
between older and younger Japanese adults with asthma. Poor adherence to inhaled 4 
medicines is affected by barriers to taking these medicines [19], [26]. In our study, 5 
adherence barriers to inhaled medicines were investigated among older and younger adults 6 
with poor adherence to medicines. Total ASK-20 scores and TBC with poor adherence were 7 
significantly higher than those with good adherence in both older and younger adults. A 8 
comparison between patients with poor and good adherence revealed that older adults 9 
reported taking medicines at fixed times (item Q1) as an independent barrier, although 10 
younger adults had three independent barriers; first, taking medicines at fixed times (item 11 
Q1); second, being concerned about the effects of medicines on their sexual health (item 12 
Q4); and third, not having their medicines on hand at the appropriate times (item Q20). The 13 
relatively simpler barriers for older adults may be associated with certain treatment beliefs 14 
among this population, which may have a strong influence on adherence in older asthmatics 15 
[15].  16 
 17 
16 
 
 Older adults had less, but not significantly so, age sub-groups with poor adherence 1 
to inhaled medicines than younger adults. Total ASK-20 scores, but not TBCs, for older 2 
adults were significantly lower than those for younger adults. A correlation between age 3 
groups with poor adherence and aging was like an inverted J-character curve with the 4 
bottom in the age groups between 75 and 84 years. An age group of 85 years and over 5 
might be an important target for reeducation for adherence, although the difference 6 
compared with the next older group, between 75 and 84 years, did not reach statistical 7 
significance due to the small sample size. The results of better adherence with aging 8 
confirmed a previous Japanese report [14]. In addition, despite having more comorbid 9 
diseases and total daily medications, older adults had better adherence than younger adults. 10 
These results were different from previous reports in Western populations that showed that 11 
adherence levels were lower with older adults with more comorbid diseases and total daily 12 
medications than with individuals of other age groups [8], [9], [10], [11], [12], [27], [28]. Our 13 
study found that over 70% of the enrolled patients were associated with good adherence to 14 
inhaled medicines and had good persistent attendance at clinics. In other Asian patients 15 
with asthma, a previous study reported embarrassment or annoyance regarding using or 16 
carrying medicines to be a barrier to inhaled medicines [26]. The better adherence among 17 
older adults may be unique to Japanese populations. 18 
17 
 
 Our analyses of each item found that about one-third of the patients reported that 1 
taking medicines on a fixed regimen (item Q16) or at specific times (item Q1), and reaching 2 
their health goals (item Q8) as barriers to inhaled medicines in both older and younger 3 
adults. The analyses also found different barriers between older and younger adults. Older 4 
adults reported that making decisions with doctors or nurses (item Q11), understanding the 5 
instructions of their medicines (item 10), and asking someone about their medicines (item 6 
Q9) as barriers more often than younger adults. Communication and partnerships between 7 
patients and physicians are an important part of achieving effective disease control [29], [30], 8 
[31], [32]. Better patient-physician communication may lead to better treatment compliance 9 
[29]. The patient-physician partnership is a contributory factor in the improvement of asthma 10 
treatment [30]. However, a previous report demonstrated that only 22% of asthmatics 11 
reported having had a good discussion with their doctor or nurse, and only 9% felt that they 12 
were given plenty of information at the time of diagnosis [31]. Another study reported that an 13 
examination of doctor-patient communications indicated that 5 to 10% of patients with 14 
asthma could not accurately recall what a caregiver had advised during their consultation 15 
[32]. Among our older patients with good adherence, better adherence may further improve 16 
communication and the partnerships with their physicians. In contrast, younger adults 17 
18 
 
identified taking medicines more or less often than prescribed and the use of alcohol as 1 
barriers. 2 
This study has some limitations. First, adherence levels were limited, because they 3 
were obtained indirectly by questionnaire and through different refill methods [21], [22], [23], 4 
[24] [25]. Second, inhalation techniques were not assessed in the study, although it is 5 
well-known that older patients are more likely to make mistakes regarding techniques when 6 
compared with younger patients [33], [34], [35]. Third, health literacy and cognitive status 7 
were not accessed [8], [9]. Previous studies found that older asthmatics with limited health 8 
literacy and cognitive impairment were associated with poorer adherence to controller 9 
medications [33], [36], [37]. Our study found that there was no difference in the disease 10 
control levels and comorbidities associated with health literacy such as psychogenic and 11 
cerebrovascular diseases between older and younger adults. Further studies are necessary 12 
to address these limitations. 13 
 14 
Conclusion 15 
We comparatively analyzed adherence barriers to inhaled medicines among older and 16 
younger patients with asthma by using the ASK-20 questionnaire. There were differences in 17 
the underlying factors for adherence barriers between older and younger patients with 18 
19 
 
asthma. Older patients with even good adherence may need more communication and 1 
stronger partnerships with physicians to improve adherence. In addition, we found different 2 
barriers between older and younger patients with poor adherence to inhaled medicines. We 3 
believe that our results will contribute to personalized education for adherence to inhaled 4 
medicines among Japanese patients with asthma. 5 
6 
20 
 
 1 
Table 1. Characteristics between older and younger adults 2 
 3 
Characteristics Total (n = 251) 
Older 
(n = 138) 
Younger 
(n = 113) p value  
Age, years 63.2 ± 14.1 73.4 ± 5.9 50.7 ± 10.6 <0.0001* 
Female, n (%) 158 (63.0) 82 (59.4) 76 (67.3) 0.2 
Body mass index, kg/m2 24.0 ± 4.6 23.7 ± 4.3 24.3 ± 4.9 0.4 
Smoking habit, Cu/Ex/Non, n (%) 29/60/162 
(11.5/23.9/64.3) 
6/38/94 
(4.4/27.5/68.1) 
23/22/68 
(20.4/19.5/60.2) 0.0003* 
Smoke index, pack-year 9.8 ± 20.2 11.5 ± 23.1 7.6 ± 15.6 0.1 
Occupation, 
Regular/Part-time/Student/Non, n 
(%) 
99/11/1/140 
(39.3/4.4/0.4/55.8) 
33/2/0/103 
(23.9/1.5/0/74.6) 
66/9/1/37 
(58.4/8.0/0.9/32.7) 
 
<0.0001* 
Any comorbid diseases, n (%) 215 (85.7) 123 (89.1) 92 (81.4) 0.1 
No. of comorbid diseases per 
patient 
2.8 ± 2.1 3.1 ± 2.3 2.4 ± 1.8 0.0050* 
Not well attention to detail in 
personality, n (%) 
37 (14.7) 15 (10.9) 22 (19.5) 0.1 
Poor concordance rates between 
visit and reserved date to clinic 
(<100%)  
65 (25.9) 30 (21.7) 35 (31.0) 0.1 
Poor controlled diseases, n (%) 72 (28.7) 35 (25.4) 24 (21.2) 0.5 
Lung function tests     
FVC, L 2.7 ± 0.8 2.4 ± 0.8 3.1 ± 0.8 <0.0001* 
% predicted FVC, % 94.2 ± 17.9 92.1 ± 19.1 96.9 ± 16.0 0.0329* 
FEV1, L 1.9 ± 0.7 1.6 ± 0.6 2.3 ± 0.7 <0.0001* 
%FEV1 predicted, % 80.1 ± 20.7 76.5 ± 21.3 84.4 ± 19.1 0.0025* 
FEV1/FVC ratio 68.7 ± 12.7 65.3 ± 12.2 72.9 ± 11.9 <0.0001* 
Regular use of medicines for 
asthma 
251 (100)    
ICS 251 (100) 138 (100) 113 (100) 1.0 
LABA 209 (83.3) 119 (86.2) 90 (79.7) 0.2 
LAMA 17 (6.8) 11 (8.0) 6 (5.3) 0.5 
CysLTRA 165 (65.7) 92 (66.7) 73 (64.6) 0.8 
slow release theophylline 57 (22.7) 29 (21.0) 28 (24.8) 0.5 
oral prednisolone 36 (14.3) 23 (16.7) 13 (11.5) 0.3 
macrolides 15 (6.0) 10 (7.3) 5 (4.4) 0.4 
mucolytic agents 53 (21.1) 37 (26.8) 16 (14.2) 0.0192* 
No. of regular inhaled devices, 
n (range) 
1.1 ± 0.4 
(1 to 3) 
1.2 ± 0.4 
(1 to 3) 
1.1 ± 0.4 
(1 to 3) 0.4 
No. of regular oral medicines,  
n (range) 
4.5 ± 3.2 
(0 to 18) 
5.2 ± 3.3 
(1 to 15) 
3.7 ± 2.9 
(0 to 18) 0.0003* 
 4 
21 
 
Notes: Data are presented as numbers (percentages) of patients and mean ± standard deviation. 1 
* p < 0.05 between older and younger adults 2 
 3 
Abbreviations: Cu/Ex/Non, current/ex/non-smoker; CysLTRA, cysteinyl leukotriene receptor 4 
antagonist; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; ICS, inhaled 5 
corticosteroid; LABA, long-acting β2 agonist; LAMA, long-acting muscarinic antagonist. 6 
 7 
8 
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 1 
Table 2 Characteristics in selected inhaled medicines by physicians 2 
between older and younger adults  3 
 4 
Selected inhaled medicines Total (n = 251) 
Older 
(n = 138) 
Younger 
(n = 113) p value  
Compounds, n (%)     
ICS monotherapy 49 (19.5) 25 (18.1) 24 (21.2) 0.6 
ICS/LABA combination therapy 202 (80.5) 113 (81.9) 89 (78.8) 0.6 
     
Devices, n (%)     
Dry powder inhalers 217 (86.5) 117 (84.8) 100 (88.5) 0.5 
Pressured-Metered dose inhalers 34 (13.6) 21 (15.2) 13 (11.5) 0.5 
     
Regimens, n (%)     
No. of administration per day     
2 times 233 (92.8) 133 (92.4) 100 (88.5) 0.0247* 
1 time 18 (7.2) 5 (3.6) 13 (11.5) 0.0247* 
Dose per one administration     
4 puffs 4 (1.6) 0 (0) 4 (3.5) 0.0399* 
3 puffs 6 (2.4) 4 (2.9) 2 (1.8) 0.7 
2 puffs 60 (23.9) 35 (25.4) 25 (22.1) 0.7 
1 puff 181 (72.1) 99 (71.7) 82 (72.6) 1.0 
 5 
Notes: Data are presented as numbers (percentages) of patients. Full data are shown in 6 
supplementary Table 1. * p < 0.05 between older and younger adults. 7 
 8 
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2 agonist. 9 
 10 
11 
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 1 
Table 3 Odds ratios of each item on independent barriers to inhaled 2 
medicines in patients with poor adherence when compared to those with 3 
good adherence to inhaled medicines 4 
 5 
 6 
Notes: Data are expressed as odds ratios (95% CI) and p values. Full analyses were shown 7 
in supplementary Tables 4A and 4B. 8 
 9 
Abbreviations: CI, confidence interval 10 
 11 
12 
item 
Older  Younger 
Odds (95% CI) p value  Odds (95% CI) p value 
Q1. I just forget to take my medicines some of the time 4.43 (1.77, 11.1) 0.0014*  6.88 (1.94, 24.4) 0.0028* 
Q4. I worry about how medicine will affect my sexual health −   7.34 (1.15, 46.6) 0.0346* 
Q20. Not had medicine with you when it was time to take it? −   4.14 (1.08, 15.9) 0.0384* 
24 
 
 1 
Figure Legends 2 
Figure 1. Study design 3 
 4 
 5 
 6 
7 
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 1 
Figure 2. Populations of patients with poor adherence to inhaled medicines 2 
 3 
 4 
 5 
Notes: A) Populations (%) of patients with poor adherence to inhaled medicines among age 6 
groups. B) Populations (%) of patients with poor adherence to inhaled medicines in the total 7 
study population, and older and younger adults. 8 
 9 
10 
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 1 
Figure 3. Comparisons in the total ASK-20 scores and TBC between older and 2 
younger adults 3 
 4 
 5 
 6 
Notes: A) Total ASK-20 scores B) TBC. Values are presented as median and 95% 7 
confidence interval (CI). Median values (upper and lower quintiles) are presented as boxes, 8 
and the maximum and minimum values of 95% CI are presented as upper and lower 9 
whiskers, respectively. Box-and-whisker plots with solid and dotted lines present the values 10 
for patients with older and younger adults, respectively. Values of outliers are presented as 11 
27 
 
open dots. 1 
 2 
Abbreviations: ASK-20, Adherence Starts with Knowledge 20; CI, confidence interval; NS, 3 
not significant; TBC, total barrier counts. 4 
 5 
6 
28 
 
 1 
Figure 4. Comparison between proportion of older and younger patients with 2 
adherence barriers to inhaled medicines identified for each ASK-20 item. 3 
 4 
 5 
Notes: Populations (%) of patients who had barriers in older and younger adults are 6 
expressed as closed and opened bars, respectively. 7 
29 
 
* p < 0.05 when comapred with younger adults; † p < 0.05 when compared with older adults. 1 
 2 
3 
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 1 
Figure 5. Total ASK-20 scores and TBC between poor and good adherence to inhaled 2 
medicines among older and younger adults 3 
 4 
 5 
31 
 
 1 
Notes: A) Total ASK-20 scores B) TBC. Values are presented as median and 95% 2 
confidence interval (CI). Median values (upper and lower quintiles) are presented as boxes, 3 
and the maximum and minimum values of 95% CI are presented as upper and lower 4 
whiskers, respectively. Box-and-whisker plots with solid and dotted lines present the values 5 
for patients with older and younger adults, respectively. Values of outliers are presented as 6 
open dots. 7 
 8 
Abbreviations: ASK-20, Adherence Starts with Knowledge 20; CI, confidence interval; TBC, 9 
total barrier counts. 10 
 11 
12 
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